

# **European Statistical Meeting Health Technology Assessment**

**June 4, 2013 Basel** 

**Hosted by Actelion** 



#### European Statistical Meeting Health Technology Assessment



#### Tuesday 4<sup>rd</sup> June 2013, Basel

Health Technology Assessment (HTA) studies the medical, social, ethical and economic implications of a health technology to a health care system, and today it is increasingly critical for manufacturers to provide additional evidence apart from that which is mandated by regulators.

This seminar will invite representatives with strong statistical backgrounds from academia, HTA bodies/regulators and industry working closely in this area. They will highlight, together with case studies, some of the key challenges in performing proper HTA research as well as where statisticians and others working in this field should be involved in helping to provide analytical and methodological leadership when establishing the evidence base that will meet the needs of both regulators and payers.

8:30am to 5:30pm



# Program - Morning session 1



09:00 – 9:05 Welcome Mike Branson (Novartis, Switzerland & BBS President)

Session chair: Fred Sorenson (Xcenda)

09:05 – 09:20 Fred Sorenson (Xcenda, Switzerland)

Health Technology Assessment – Why is it so important?

09:20 – 10:00 Matthias Egger (Univ. of Bern, Switzerland) and Mike Chambers (GSK, UK)

Moving HTA forward: The Challenges of Incorporating Real World Evidence into Health Technology Assessment

10:00 – 10:30 Claudia Nicolay (Lilly, Germany)

Health Technology Assessment - What's in for Stats?

10:30 – 10:45 Coffee break



# Program – Morning session 2



Session chair: Marisa Bacchi (Actelion) representing BBS

10:45 – 11:15 Jens Grüger (Roche, Switzerland)

HTA and personalized healthcare

11:15 – 11:45 Skip Olson (Novartis, Switzerland)

HTA - Use of observational, retrospective or prospective studies

11:45 - 13:00 Lunch break



# Program - Afternoon session 1



Session chair: Chrissie Fletcher (Amgen) representing EFSPI & PSI HTA SIG

13:00 – 13:30 Bruno Falissard (Univ. of S. Paris & INSERM, France)

The place of subjectivity in the French system (HAS): a good thing or an archaism?

13:30 – 14:00 Ralf Bender (IQWiG, Germany)

Biometrical topics of Health Technology Assessment in Germany

14:00 – 14:30 Friedhelm Leverkus (Pfizer, Germany)

30 Months AMNOG Health Technology Assessment: Outcomes and Issues

14:30 - 14:45 Coffee break



### Program – Afternoon session 2



Session chair: Egbert Biesheuvel (MSD, Netherlands & EFSPI Chair, Scientific Committee)

15:00 – 15:30 Lou Garrison (Univ. of Washington, USA)

HTA in Emerging Markets: A Framework and Examples

15:30 – 16:00 Richard Nixon (Novartis, Switzerland)

Using early health economic models to support drug development decisions

16:00 – 16:30 Chrissie Fletcher (Amgen, UK)

Using indirect treatment comparisons to support an HTA



## Program – Afternoon session 3



#### 16:30 - 17:05 Panel Discussion:

Implications of healthcare reform on HTA in the United States

- Tommy Bramley, Senior VP and head of scientific consulting (Xcenda, US)
- John Doyle, Senior VP and head of consulting (Quintiles, US)
- Lou Garrison, Prof. Depts. of Pharmacy, Global Health and Health Services (Univ. of Washington, US)
- Ansgar Hebborn, Head, Global Payer & HTA Program Policy (Roche, Switzerland)
- Skip Olson, Global Head HE&OR, Neuroscience and Ophthalmology (Novartis, Switzerland)

Moderators: François Aubin (Past EFSPI President and Head of Biometry, Cardinal Systems, France) and Fred Sorenson (Xcenda, Switzerland)

17:05 Concluding remarks Uli Burger (Roche, Switzerland)

17:10 Adjourn



#### **BBS & EFSPI**



Would like to thank you!

in particular the speakers, organisers and host

#### Hope you've enjoyed it & have a safe trip home!

Please fill in the survey that will be sent to you
 (already available at: <a href="http://www.surveymonkey.com/s/9RLZRVX">http://www.surveymonkey.com/s/9RLZRVX</a>)

In case you need any assistance, please let us know